S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
NASDAQ:BGNE

BeiGene - BGNE Stock Forecast, Price & News

$193.97
-2.67 (-1.36%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$192.01
$199.60
50-Day Range
$130.30
$202.24
52-Week Range
$118.18
$426.56
Volume
163,745 shs
Average Volume
230,051 shs
Market Capitalization
$20.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$299.25

BeiGene MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
54.3% Upside
$299.25 Price Target
Short Interest
Bearish
2.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.14mentions of BeiGene in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$1.12 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($16.95) to ($11.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

952nd out of 1,135 stocks

Pharmaceutical Preparations Industry

475th out of 557 stocks

BGNE stock logo

About BeiGene (NASDAQ:BGNE) Stock

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Wall Street Analyst Weigh In

Several brokerages recently commented on BGNE. StockNews.com upgraded shares of BeiGene from a "sell" rating to a "hold" rating in a report on Monday, August 8th. JPMorgan Chase & Co. restated an "overweight" rating and set a $296.00 price objective on shares of BeiGene in a report on Tuesday. Finally, Morgan Stanley dropped their price objective on shares of BeiGene from $300.00 to $293.00 and set an "overweight" rating on the stock in a report on Friday, July 15th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $299.25.

BeiGene Stock Performance

NASDAQ:BGNE opened at $193.97 on Friday. The stock has a market cap of $20.07 billion, a P/E ratio of -9.50 and a beta of 0.66. The company's 50-day simple moving average is $169.47 and its 200 day simple moving average is $176.95. BeiGene has a twelve month low of $118.18 and a twelve month high of $426.56. The company has a quick ratio of 4.87, a current ratio of 4.54 and a debt-to-equity ratio of 0.03.

Insider Activity at BeiGene

In other BeiGene news, CFO Julia Aijun Wang sold 295 shares of the business's stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $158.50, for a total value of $46,757.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Lai Wang sold 660 shares of the company's stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $142.00, for a total transaction of $93,720.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Julia Aijun Wang sold 295 shares of the stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $158.50, for a total transaction of $46,757.50. The disclosure for this sale can be found here. Insiders have sold a total of 7,740 shares of company stock valued at $1,124,135 over the last quarter. 7.50% of the stock is owned by company insiders.

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Stock News Headlines

BeiGene (NASDAQ:BGNE) Upgraded at StockNews.com
Recap: BeiGene Q2 Earnings - Benzinga
BeiGene Reports Second Quarter 2022 Financial Results
Why BeiGene (BGNE) Might Surprise This Earnings Season
BeiGene (NASDAQ:BGNE) Shares Gap Down to $168.08
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Company Calendar

Last Earnings
11/04/2021
Today
8/14/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
8,200
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$299.25
High Stock Price Forecast
$431.00
Low Stock Price Forecast
$177.00
Forecasted Upside/Downside
+54.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-1,413,350,000.00
Net Margins
-187.65%
Pretax Margin
-187.04%

Debt

Sales & Book Value

Annual Sales
$1.18 billion
Book Value
$51.25 per share

Miscellaneous

Free Float
95,709,000
Market Cap
$20.07 billion
Optionable
Optionable
Beta
0.66

Social Links


Key Executives

  • Mr. John V. Oyler (Age 54)
    Co-Founder, Exec. Chairman & CEO
    Comp: $1.75M
  • Dr. Xiaobin Wu Ph.D. (Age 60)
    Pres, COO & GM of China
    Comp: $1.64M
  • Dr. Xiaodong Wang Ph.D. (Age 59)
    Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director
    Comp: $250k
  • Ms. Julia Wang (Age 51)
    CFO & Principal Accounting Officer
    Comp: $798.14k
  • Mr. Wang Lai (Age 45)
    Global Head of R&D
    Comp: $1.13M
  • Dr. Edna Huang M.D. (Age 49)
    Consultant
    Comp: $768.08k
  • Mr. Daniel Maller
    VP of Fin. & Accounting
  • Ms. Mi Zhou
    Sr. Director of Investor Relations
  • Mr. Kevin C. Mannix
    Sr. VP of Investor Relations.
  • Ms. Diana Lee Francis
    VP and Global Head of Quality & Regulatory Compliance













BGNE Stock - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BGNE shares.
View BGNE analyst ratings
or view top-rated stocks.

What is BeiGene's stock price forecast for 2022?

6 analysts have issued 12 month price targets for BeiGene's stock. Their BGNE share price forecasts range from $177.00 to $431.00. On average, they expect the company's share price to reach $299.25 in the next year. This suggests a possible upside of 54.3% from the stock's current price.
View analysts price targets for BGNE
or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2022?

BeiGene's stock was trading at $270.93 on January 1st, 2022. Since then, BGNE stock has decreased by 28.4% and is now trading at $193.97.
View the best growth stocks for 2022 here
.

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our BGNE earnings forecast
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($4.46) earnings per share for the quarter, topping analysts' consensus estimates of ($4.70) by $0.24. The company earned $206.44 million during the quarter, compared to analysts' expectations of $185.70 million. BeiGene had a negative net margin of 187.65% and a negative trailing twelve-month return on equity of 38.58%.

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by many different retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (3.90%), Baillie Gifford & Co. (3.13%), FMR LLC (2.80%), Artal Group S.A. (0.63%), Bridgewater Associates LP (0.32%) and Pictet Asset Management SA (0.30%). Insiders that own company stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends
.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $193.97.

How much money does BeiGene make?

BeiGene (NASDAQ:BGNE) has a market capitalization of $20.07 billion and generates $1.18 billion in revenue each year. The company earns $-1,413,350,000.00 in net income (profit) each year or ($20.42) on an earnings per share basis.

How many employees does BeiGene have?

The company employs 8,200 workers across the globe.

When was BeiGene founded?

BeiGene was founded in 2010.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for the company is www.beigene.com. The company can be reached via phone at 861085148500 or via email at ir@beigene.com.

This page (NASDAQ:BGNE) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.